Basal18 F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment

Abstract Aim To analyze the relationship of clinical variables related to prognosis and tumor burden, with metabolic variables obtained in the staging18 F-FDG PET/CT, and their value in the prognosis in follicular lymphoma (FL). Methods 82 patients with FL, a18 F-FDG PET/CT at diagnosis and a follow...

Full description

Saved in:
Bibliographic Details
Published in:Revista Española de medicina nuclear e imagen molecular (English ed.) Vol. 35; no. 5; pp. 298 - 305
Main Authors: Jiménez Londoño, G.A, García Vicente, A.M, Poblete García, V.M, Amo-Salas, M, Calle Primo, C, Ibañez García, Á, Martínez Sanchís, B, López-Fidalgo, J.F, Solano Ramos, F, Martínez Hellín, A, Díaz Morfa, M, Soriano Castrejón, Á
Format: Journal Article
Language:English
Published: 2016
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim To analyze the relationship of clinical variables related to prognosis and tumor burden, with metabolic variables obtained in the staging18 F-FDG PET/CT, and their value in the prognosis in follicular lymphoma (FL). Methods 82 patients with FL, a18 F-FDG PET/CT at diagnosis and a follow-up for a minimum of 12 months, were retrospectively enrolled in the present study. Clinical variables (Tumor grade, Follicular Lymphoma International Prognostic Index (FLIPI) and Tumor burden) were evaluated. Metabolic variables such as SUVmax in the highest hypermetabolic lesion, extralymphatic locations, number of involved lymph node locations, bone marrow (BM) involvement, PET stage and diameter of the biggest hypermetabolic lesion, were analyzed in order to establish a PET score and classify the studies in low, intermediate and high metabolic risk. Clinical and metabolic variables (included metabolic risk) were compared. The relation among all variables and disease-free survival (DFS) was studied. Results The 28% of patients had a high-grade tumor. The 30.5% had FLIPI risk low, 29.3% intermediate y 40.2% high. The 42.7% presented a high tumor burden. The PET/CT was positive in 94% of patients. The tumor grade did not show significant relation with metabolic variable. FLIPI risk and tumor burden showed statistical relations with the SUV max and the PET score ( p < 0.008 and p = 0.003 respectively). With respect to DFS, significant differences were detected for the PET stage and FLIPI risk ( p = 0.015 and p = 0.047 respectively). FLIPI risk was the only significant predictor in Cox regression analysis, with a Hazard Ratio of 5.13 between high risk and low risk. Conclusion The present research highlights the significant relation between metabolic variables obtained with FDG PET/CT and clinical variables although their goal as an independent factor of prognosis was not demonstrated in the present work.
ISSN:2253-8089
2253-8089
DOI:10.1016/j.remnie.2016.04.007